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ABSTRACT: Many of the functional proteins and lipids in high density
lipoprotein (HDL) particles are potentially glycosylated, yet very little is known
about the glycoconjugates of HDL. In this study, HDL was isolated from
plasma by sequential micro-ultracentrifugation, followed by glycoprotein and
glycolipid analysis. N-Glycans, glycopeptides, and gangliosides were extracted
and purified followed by analysis with nano-HPLC Chip quadrupole time of
flight mass spectrometry and MS/MS. HDL particles were found to be highly
sialylated. Most of the N-glycans (∼90%) from HDL glycoproteins were
sialylated with one or two neuraminic acids (Neu5Ac). The most abundant N-
glycan was a biantennary complex type glycan with two sialic acids
(Hexose5HexNAc4Neu5Ac2) and was found in multiple glycoproteins using
site-specific glycosylation analysis. The observed O-glycans were all sialylated,
and most contained a core 1 structure with two Neu5Acs, including those that
were associated with apolipoprotein CIII (ApoC-III) and fetuin A. GM3 (monosialoganglioside, NeuAc2−3Gal1−4Glc−Cer)
and GD3 (disialoganglioside, NeuAc2−8NeuAc2−3Gal1−4Glc−Cer) were the major gangliosides in HDL. A 60% GM3 and
40% GD3 distribution was observed. Both GM3 and GD3 were composed of heterogeneous ceramide lipid tails, including
d18:1/16:0 and d18:1/23:0. This report describes for the first time a glycomic approach for analyzing HDL, highlighting that
HDL are highly sialylated particles.
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■ INTRODUCTION
High density lipoprotein (HDL) particles have been considered
to be atheroprotective due to their role in reverse cholesterol
transport; however, many other functions including toxin
binding, antioxidant, anti-inflammatory, antiglycation, antith-
rombotic, and immunomodulatory functions have recently
been described.1 HDL particles are heterogeneous, and yet the
molecular and functional bases behind the large degree of
variability among the different classes and subclasses of HDL
particles have not been established.2 A key challenge facing the
field of lipoprotein biology is that chemical, compositional, and
structural changes can transform atheroprotective HDL into
pro-atherogenic, pro-inflammatory particles.3 Under inflamma-
tory conditions, HDL particles are ineffective at reverse
cholesterol transport despite high plasma HDL concentrations.4
The antioxidant function of HDLprotection of low density
lipoprotein (LDL) from oxidationis impaired in heart disease
patients.5 Dysfunctional HDL with impaired antioxidant and
endothelial protection are found in type 2 diabetes patients.6
HDL from patients with cardiovascular disorders are composi-
tionally different from those of healthy individuals.7,8 In
addition, the antimicrobial, anti-inflammatory, antiglycation,
antithrombotic, and immunomodulatory functions of HDL and
how these are modified by HDL composition are poorly
understood.
As complex multimolecular aggregates, many of the func-
tional proteins and lipids in HDL are potentially glycosylated.
Yet, very little is known about these glycoconjugates of HDL.
There is evidence that ApoA-I, A-II, C-I, C-II, and C-III are all
glycosylated.9 Glycosylation of ApoA may be important for the
secretion of HDL from the liver10 and may influence its
association/dissociation properties to HDL particles: sialylated
ApoA-II associated only with HDL3 , whereas nonsialylated
ApoA-II associated with HDL of all sizes.11 Desialylation of
ApoE is associated with hepatic steatosis.12 ApoE Leiden, an
aberrantly glycosylated variant of ApoE, shows defective
binding to the LDL receptor.13 Decreased sialic acid in
cerebrospinal fluid ApoE was found with aging and was
associated with smaller lipoprotein particle sizes, which may be
involved in the formation of amyloid plaque.14 Loss of sialic
acid α2,6-Neu5Ac containing structures in ApoC-III was found
in lung cancer patients.15 Serum amyloid A (SAA), which is
released in response to acute phase immune reaction, circulates
primarily as a constituent of HDL particles.16 An N-
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glycosylated form of SAA that is distinct from acute phase SAA
has been described.17 These data suggest important as yet not
fully characterized mechanistic links between the glycosylation
of HDL-associated glyocoproteins and HDL function. How-
ever, the glycosylation of the HDL proteome has not been
characterized.
Gangliosides are glycolipids containing sialic acids in their
carbohydrate moieties. Bacterial toxins display a heterogeneous
specificity of binding to their glycolipid receptors.18 For
example, lactosylceramide and ganglioside GM3 bind several
enterotoxigenic strains of Escherichia coli.19 Twenty-five percent
of serum gangliosides were reported to be associated with HDL
in human serum, with a different compositional profile for HDL
compared with other circulating lipoproteins (e.g., very low
density lipoprotein (VLDL) and LDL) and serum.20 However,
only limited information is available on the occurrence of these
ganglioside species in plasma HDL and whether and how they
vary with disease.
Studies of the HDL proteome have uncovered an array of
110 proteins that are thought to be associated with HDL
particles. In fact, it is now thought that different subsets of HDL
particles, separated in different waysultracentrifugation,
electrophoretic migration, immunoaffinity chromatography,
size exclusion chromatography, and othersare characterized
by different proteomes.21 However, although the proteins that
associate with HDL have been identified and for some of these
proteins the glycosylation has been characterized independ-
ently, to date, there have been no direct investigations of the
overall glycome of HDL.
In this article, we describe an analytical strategy that is
detailed and quantitative, comprehensively examining the
glycan structures on glycoproteins and glycolipids of HDL.
Previously, no adequate methods to determine HDL glycan
diversity as a whole in a clinically relevant manner existed.
Methods for elucidating the complete HDL glycome using a
combination of nanoflow liquid chromatography and high
performance mass spectrometry for the simultaneous identi-
fication and quantification of glycoconjugates in HDL particles
are described. On the basis of the glycosylation discovered, we
propose a new model for HDL as a class of highly sialylated
particles.
■ EXPERIMENTAL PROCEDURES
A comprehensive glycome analysis workflow is summarized in
Figure 1 and described below.
HDL Isolation
Fasting (12 h) blood samples were obtained from a healthy
study participant as part of an ongoing approved protocol to
collect fasting plasma from healthy subjects for methods
development. Briefly, healthy subjects are recruited on the
University of California Davis campus by flyering and
announcements at seminars. Subjects are screened for basic
eligibility criteria (healthy, able to give blood, and not taking
any medications) and provide written informed consent to
participate in the study. The Institutional Review Board of the
University of California Davis approved the study protocol. The
study was conducted according to the principles expressed in
the Declaration of Helsinki.
Preparation of HDL was performed by a sequential micro-
ultracentrifugation method described by Brousseau et al.22 with
slight modifications. Blood was collected from the antecubital
vein into EDTA evacuated tubes, centrifuged immediately
(1300g, 10 min, 4 °C), portioned into aliquots, and stored at
−80 °C until analyzed. Three thawed replicate plasma samples
(0.8 mL each as triplicates) were gently overlaid on the KBr
solution to avoid the introduction of air. To isolate the
combined VLDL and LDL fractions, potassium bromide (KBr)
solution (1.1 mL, d = 1.084 g/mL) was transferred into cone-
top polyallomer tubes up to the 1.9 mL neckline. Ultra-
centrifugation was performed using a Sorvall RC M120 GX
equipped with a S120-AT2 fixed-angle rotor (Thermo
Scientific, Waltham, MA, USA) for 2.5 h, 8 °C, 435680g. By
this procedure, the combined VLDL and LDL fractions with a
density lower than 1.060 g/mL were removed from the top of
the tubes (0.9 mL) by aspiration using a gel-loading pipet
(Rainin, Oakland, CA, USA). The remaining infranate (1.0
mL) was transferred into new cone-top polyallomer tubes. To
Figure 1. HDL glycome analysis workflow.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr4012393 | J. Proteome Res. 2014, 13, 681−691682
isolate the HDL fraction, the transferred infranate was overlaid
with 0.9 mL of KBr solution (d = 1.34 g/mL) and
ultracentrifugation was performed (3 h, 8 °C, 435680g). The
HDL fraction (1.2−1.063 g/mL) was identified as the top 0.6
mL layer found at the top of the tubes. The HDL fraction was
collected from the top of the tube (0.6 mL) and desalted using
an Amicon dialysis membrane with a molecular weight cutoff of
3000 (Millipore, Billerica, MA, USA) in nanopure water (18
Ω), prior to being dried down and reconstituted with 300 μL of
water.
Density solutions of KBr, at d = 1.084 g/mL and 1.34 g/mL
were made weekly and adjusted and verified by measurement
using a Densito 30PX portable densitometer (Mettler Toledo,
Columbus, OH, USA). Thirteen replicates of plasma samples
isolated from fasted and fed healthy human subjects were
measured by the Densito 30PX to verify the density of plasma.
The mean ± SEM density of the plasma samples was 1.027 ±
0.0005 g/mL.
Glycoprotein Analysis
Tryptic Digestion. A total of 100 μL of 50 mM ammonium
bicarbonate solution was added to 10 μL of isolated HDL,
followed by reducing with 5 μL of 550 mM dithiothreitol
(DTT) with incubation for 50 min at 60 °C. A total of 10 μL of
450 mM iodoacetamide (IAA) was then added, and
carboxymethylation was performed by incubation for 20 min
at room temperature in the dark. Reduced and carboxymethy-
lated HDL was digested using sequencing grade modified
trypsin (Promega, Madison, WI, USA) 2 μL (1 μg/μL) in 100
μL of 50 mM ammonium bicarbonate buffer, for 16 h at 37 °C.
The digests were purified on a reverse-phase cleanup C18 pipet
tip (Agilent Technology, Wilmington, DE, USA). The C18 zip-
tip was preconditioned successively with acetonitrile (150 μL,
10 times) and water (150 μL, 10 times). The tryptic digest was
loaded onto the zip-tip by pipetting 20 times up and down and
then washed with water (150 μL) 10 times. HDL tryptic
peptides were eluted with 0.05% formic acid (FA) in 80%
acetonitrile (ACN) in water (v/v) (200 μL, 20 times
extractions), dried down, and then reconstituted in 20 μL of
nanopure water.
N-Linked Glycan Release and Purification. N-Linked
glycans were released from 60 μL of HDL in 200 μL of 100
mM ammonia bicarbonate buffer using endoglycosidase
PNGase F (New England Biolabs, Ipswich, MA, USA) (2
μL) for 10 min under microwave condition (power 20 W,
temperature 60 °C). The released N-glycans were cleaned up
via solid phase extraction (SPE) using graphitized carbon
cartridges (Grace Davison Discovery Sciences, Deerfield, IL,
USA). The glycan digest was loaded on preconditioned
graphitized carbon cartridges then washed with 6 mL of
nanopure water. N-Glycans were eluted with 6 mL of 0.05%
trifluoroacetic acid (TFA) in 40% ACN in water (v/v) dried
down, and then reconstituted in 20 μL of nanopure water prior
to MS analysis.
Pronase Digestion and Glycopeptide Cleanup. A total
of 100 μg of Pronase E was covalently coupled to cyanogen
bromide (CNBr)-activated sepharose beads (Sigma-Aldrich, St.
Louis, MO, USA) via coupling chemistry and as earlier reported
in our laboratory.23−26 A total of 100 μL of isolated HDL was
added to the Pronase beads, and the the mixture was incubated
at 37 °C for 18 h. Pronase would normally digest the
glycoproteins to glycopeptides with the peptide portion 1−20
amino acids. The glycopeptide digest was desalted and enriched
via an SPE procedure using graphitized carbon cartridges.
Similar to the N-glycan cleanup procedure, followed by
conditioning the cartridges using acetonitrile and water and
loading the digest mix, a clean mixture of glycopeptides was
eluted in 9 mL of 0.05% TFA in 40% ACN in water (v/v),
dried down, and then reconstituted in 20 μL of nanopure water
prior to MS analysis.
Ganglioside Analysis
Extraction of Gangliosides. A total of 100 μL of isolated
HDL was mixed with 1 mL of water, 2.7 mL of methanol and
1.3 mL of chloroform, and the mixture was shaken vigorously
for 5 s. After centrifugation at 3000g for 5 min, 0.5 mL of water
was added for the phase separation. The supernatant was
collected. The bottom organic layer was re-extracted using 5
mL of 3:4:8 water/chloroform/methanol (v:v:v) and mixed,
and then the supernatants were pooled and dried.
A C8 SPE cartridge (Supelco, Bellefonte, PA, USA) was
conditioned with 6 mL of 1:1 isopropanol/methanol (v/v) and
1:1 methanol/water (v/v). The sample was diluted with 1 mL
of 1:1 methanol/water (v/v) and applied to the SPE cartridge.
The cartridge was washed with 9 mL of 1:1 methanol/water
(v/v) solution to ensure removal of all polar compounds. The
gangliosides were eluted by washing 9 mL of 1:1 isopropanol/
methanol (v/v), and the eluant was evaporated to dryness. The
purified sample was stored at −80 °C until analysis.
Instrumentation
A nano-HPLC Chip Q-TOF instrument using the Agilent 1200
series microwell-plate autosampler (maintained at 6 °C by the
thermostat), capillary pump, nano pump, HPLC Chip interface,
and the Agilent 6520 Q-TOF MS (Agilent Technologies, Inc.,
Santa Clara, CA) was used in this study.
For the tryptic peptide and the ganglioside analyses, a
reverse-phase nano-HPLC Chip (G4240-62001, Agilent
Technologies, Inc., Santa Clara, CA) with a 40 nL enrichment
column and 43 × 0.075 mm ID analytical column was used.
The column was packed with ZORBAX C18 (5 μm pore size)
stationary phase. The mobile phase for tryptic peptides
consisted of 0.1% formic acid in 3% ACN in water (v/v) as
solvent A, and 0.1% formic acid in 90% ACN in water (v/v) as
solvent B. The mobile phases used for gangliosides were water
(solvent C) and 15% isopropanol in methanol (v/v) (solvent
D), with both containing 20 mM ammonium acetate and 0.1%
acetic acid. The nano pump gradient was performed on the
analytical column to separate the tryptic peptides with a flow
rate at 0.4 μL/min and the gangliosides with 0.3 μL/min. The
peptides were eluted in 45 min with the following gradient: 0%
B (0.00−2.50 min); 0−16% B (2.50−20.00 min); 16−44% B
(20.00−30.00 min); 44−100% B (30.00−35.00 min) and 100%
B (35.00−45.00 min). The gradient used for gangliosides
separation was as follows: 70% of D (0.00−1.00 min); 70−80%
D (1.00−3.00 min); 80−100% D (3.00−40.00 min); and 100%
D (40.00−45.00 min). The working samples were dissolved in
water/methanol (1:1, v/v).
For the N-glycan and the Pronase glycopeptide analysis, an
Agilent 6210 HPLC Chip II with a 40 nL enrichment column
and 43 × 0.075 mm ID analytical column both packed with
porous graphitized carbon stationary phase was used. The
mobile phase consisted of 0.1% formic acid in 3% ACN in
water as solvent A and 0.1% formic acid in 90% ACN in water
(v/v) as solvent B. The nano pump gradient was performed on
the analytical column to separate the N-glycans and
glycopeptides with a flow rate at 0.4 μL/min. The samples
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were eluted in 45 min with the following gradient: 0% B (0.00−
2.50 min); 0 to 16% B (2.50−20.00 min); 16 to 44% B (20.00−
30.00 min); 44 to 100% B (30.00−35.00 min) and 100% B
(35.00−45.00 min).
The Agilent 6520 Q-TOF MS was operated in the positive
ion mode for MS and MS/MS modes for the tryptic peptides,
N-glycans, and Pronase glycopeptides. The recorded mass
ranges were m/z 500−3000 for MS only and m/z 50−3000 for
MS/MS. Acquisition rates were 0.63 spectra/s for both MS and
MS/MS. For gangliosides, MS was operated in the negative
mode, and MS/MS was operated in both positive and negative
modes. The recorded mass ranges were m/z 500−2500 for MS
only and m/z 50−1500 for MS/MS. The drying gas
temperature was set at 325 °C with a flow rate of 4 L/min.
All mass spectra were internally calibrated using the G1969−
85000 ESI tuning mix (Agilent Technologies, Inc., Santa Clara,
CA), with reference masses at m/z 922.010 and 1521.971 in the
positive ion mode, at m/z 680.036 and 1279.995 for the
negative mode.
In MS/MS mode, generally, the collision energies for the
tryptic peptides, N-glycans, and Pronase glycopeptides were
calculated as
= −⎜ ⎟⎛⎝
⎞
⎠V V
m z
3.6
/
100Da
4.8 V (tryptic peptides)collision
= − ‐⎜ ⎟⎛⎝
⎞
⎠V V
m z
1.8
/
100Da
4.8 V (N glycans and Pronase 
glycopeptides)
collision
For gangliosides, data-dependent MS/MS analysis was
performed with collision energies set at 40 V for the negative
mode and 80 V for the positive mode.
Data Analysis
All tryptic MS/MS data were analyzed using X! Tandem (www.
thegpm.org). Trypsin digesion would help identify the HDL-
associated proteins. X! Tandem was set up to search the
Swissprot human complete proteome set database. X! Tandem
was searched with a fragment ion mass tolerance of 80 ppm and
a parent ion tolerance of 100 ppm. Iodoacetamide derivative of
cysteine was specified in X! Tandem as a fixed modification.
Deamidation of asparagine and glutamine, oxidation of
methionine and tryptophan were specified in X! Tandem as
variable modifications.
Data analyses for N-glycans, glycopeptides, and gangliosides
were performed with the MassHunter Qualitative Analysis
software ver. B.03.01 (Agilent Technologies, Inc., Santa Clara,
CA).
For the N-glycan analysis, within a 20 ppm accurate mass
criterion molecular feature extraction (MFE) was performed
through a mode of the “Find by Molecular Feature” function
for nontargeted profiling. The deconvoluted glycan mass,
retention time, and abundance were extracted. The glycan
compositions were assigned based on the accurate mass and the
corresponding MS/MS data.
Glycopeptide assignments were achieved by the combination
of the tandem MS information and the accurate glycopeptide
precursor ion mass via in-house software GP Finder. The mass
list of the glycopeptides precursor ions was analyzed with
accurate mass, protein sequence, biological filters of glycans,
and a MS tolerance level (≤20 ppm). The tandem mass spectra
were then taken into account for further inspection with glycan
and peptide fragmentation patterns with a mass tolerance for
fragment ions (≤80 ppm). The unique significance of GP
Finder is to use a false discovery rate by generating a decoy
library to the scoring system and to serve as a more reliable
means of making assignments.
Figure 2. Overlaid extracted compound chromatograms (ECCs) showing the profile of human HDL glycans via nano-LC−MS. Green circles, yellow
circles, blue squares, red triangles, and purple diamonds represent mannose, galactose, GlcNAc, fucose, and NeuAc residues, respectively.
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For gangliosides, MFE was performed to generate a peak list
(m/z, retention time, and peak area) taking all ions into
account exceeding 1000 counts. Focused postprocessing
precursor ion scan analysis was performed through a mode of
the “Find by Auto MS/MS”. The NeuAc ions (m/z 290.095)
were the fragment ions used to determine the precursor ion
masses representing gangliosides.
■ RESULTS AND DISCUSSION
HDL particles remain poorly characterized due to their size,
complexity, dynamic nature, and large degree of diversity in
composition and function. Enabling technologies that can be
used to comprehensively analyze these biologically important
particles are needed. In particular, very little is known about the
biological functions related to the glycosylated components of
HDL. This deficiency in understanding the glycobiology of
HDL may be critically important since early published evidence
indicates that both glycoproteins and glycolipids associated
with HDL and their variation in glycosylation patterns may be
either mechanistically involved or diagnostic of HDL functions.
In this study, HDL particles isolated from healthy human
plasma were comprehensively examined for their glycan
structures, and the results led to a compelling new model of
HDL as a class of highly sialylated particles.
Proteomics Analysis
Tryptic peptides were digested from HDL fractions isolated by
ultracentrifugation. After high-performance liquid chromatog-
raphy (HPLC) separation via reversed phase C18 column, the
peptides were analyzed by tandem MS. Following a database
search, 17 proteins were identified shown in Supplemental
Table S1, Supporting Information from one replicate as an
example. The base −10 log of the expectation that any
particular protein assignment was made at random was lower
than −2. ApoA-I was observed as the major protein. In humans,
about 60% of the protein content in HDL is represented by
ApoA-I.27 Other apoproteins were present, including Apo C-II,
C-III, D, E, and M, which are typical minor apoproteins
associated with HDL. On the other hand, ApoB-100, the major
constituent of VLDL and LDL, was not present. Other proteins
known to be associated with HDL were also observed,
including acute phase response proteins such as SAA, liver
secreted proteins such as alpha-2-HS-glycoprotein (fetuin A),
and the key mediators of the complement system C3
inhibitor.28−31 The proteins associated with HDL isolated
from healthy human plasma in this study have all been
suggested as HDL-associated proteins in previous studies.32−35
These results confirmed our HDL isolation approach and
provided a list of proteins for site-specific glycosylation analysis.
Glycans from HDL Compositionally Profiled by
Nano-LC−MS
The N-glycans were released using the protocol described in
Experimental Procedures. Analyses were done from the isolated
HDL triplicates. The glycan profile of HDL is illustrated with
one of the triplicates (Figure 2). The depicted glycan structures
were based on biological precedence and their correct masses;
however, isomers are putative.36 HPLC-microchip packed with
a PGC stationary phase was used to separate glycans with high
sensitivity and reproducibility.37−40 The total ion chromato-
gram (TIC) from the raw LC−MS data was separated into a
number of extracted compound chromatograms (ECCs). The
extractor algorithm was based on the expected charge carriers,
potential neutral mass losses, and a predicted isotopic
Table 1. List of HDL Glycans with Retention Times, Their m/z Values, Charge States, Glycan Compositions, and the Ion
Intensities
retention time (min) measured m/z charge state mass error (ppm) hexose HexNAc fucose NeuAc ion intensity (counts)
24.839 1112.403 2 3.57 5 4 0 2 6091078
23.541 1112.402 2 2.94 5 4 0 2 4906932
19.915 966.8551 2 4.13 5 4 0 1 1196125
18.466 966.8576 2 6.78 5 4 0 1 797081
22.675 966.8543 2 3.37 5 4 0 1 129647
17.355 966.8556 2 4.65 5 4 0 1 78041
17.725 865.3141 2 3.12 5 3 0 1 171480
16.31 865.3134 2 2.38 5 3 0 1 47271
24.524 1039.883 2 2.91 5 4 1 1 141126
22.706 1039.883 2 2.99 5 4 1 1 95666
23.434 1039.884 2 3.92 5 4 1 1 41850
20.862 1039.878 2 −1.68 5 4 1 1 19297
17.857 894.3368 2 4.97 5 4 1 0 140215
16.374 894.3332 2 0.98 5 4 1 0 58633
15.169 821.3112 2 9.56 5 4 0 0 93233
13.997 821.3069 2 4.31 5 4 0 0 43677
25.483 1185.427 2 −0.37 5 4 1 2 62932
19.253 784.2855 2 0.65 4 3 0 1 55095
16.874 813.3067 2 0.92 4 4 1 0 53118
19.206 885.8271 2 2.78 4 4 0 1 48338
17.746 885.8248 2 0.15 4 4 0 1 24690
12.726 942.3367 2 7.5 9 2 0 0 38575
11.579 942.3349 2 5.58 9 2 0 0 16327
23.563 1258.465 2 6.4 5 4 2 2 37927
21.401 1076.901 2 2.33 6 5 1 0 30048
24.534 1294.957 2 −5.19 6 5 0 2 25651
16.092 732.2802 2 0.95 3 4 1 0 22085
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distribution. Each peak represents one compound eluting at a
certain retention time with the detected m/z, which enables the
assignments of glycan composition.
The most abundant glycan (including isomers) was a
biantennary complex type glycan with two sialic acids
(Hexose5HexNAc4Neu5Ac2). Perhaps not surprisingly, these
glycans are also the most abundant in blood.36 In this regard,
HDL-associated proteins are similar to other abundant
glycoproteins in blood.41 Two abundant isomers were observed
eluting at retention times 23 and 25 min. Most of the glycans
(90%) from HDL glycoproteins were sialylated with one or two
Neu5Ac(s). Ion intensities were measured in the MS mode
based on the protonated molecular ion in positive mode (Table
1). Following the most abundant glycan with two Neu5Ac, a
complex type biantennary glycan with one Neu5Ac was shown
in a high intensity eluting at 17−20 min including four
observed isomers. Our group reported glycans with sialic acids
are retained longer with PGC.39 Here we also observed that the
sole addition of an acidic NeuAc residue increased the retention
time by nearly 5 min.
Sialic acid, mostly found as a terminal component of
glycoproteins and glycolipids on the outer surface of cells, is
involved in cellular secretions.42 Sialic acid participates in
multiple and diverse cellular events, such as acting as an
antirecognition agent by shielding recognition sites42−44 and
conversely by being a biological recognition site as a ligand for
multiple molecules.45,46 Sialic acid is anionic and therefore
likely contributes to HDL’s negative charge. Previously, it has
been shown that the addition of phosphatidylinositol, which
increases HDL’s negative charge, blocked binding of HDL to
hepatic lipase.47 Other previous studies have also shown that
the electronegativity of HDL affects its binding to cholesterol
ester transfer protein and thus the exchange of cholesterol
esters with LDL.48 The sialylated glycans in HDL associated
proteins may be involved in molecular and cellular interactions
that affect the function of HDL. For example, sialic acid
residues of ApoE may be essential for its recognition by HDL3
particles and further the binding to HDL3.
49 Interestingly,
desialylation of lipoprotein-associated apoproteins was found to
be associated with increased circulating neuraminidase excreted
by Streptococcus pneumonia in patients with hemolytic uremic
syndrome,50 suggesting that bacterial infection may lead to
desialylation of HDL particles in vivo.
In addition to complex-type sialylated N-glycans, fucosylated
N-glycans were present at relatively low abundances. High-
mannose and hybrid type N-glycans were also observed,
indicating the variety of N-glycans from HDL-associated
proteins. The wide dynamic range of the detected N-glycans
by the described method allows the evaluation of all types of
oligosaccharides and further analyses of their biological
functions.
Supplemental Figure S1, Supporting Information shows the
overlaid ECCs of N-glycans from the three replicates. The
separation of glycans and their profiles was similar, as the most
abundant ones were observed as sialylated complex-type eluting
at 23−25 min. The method is considered reproducible with
regard to the glycan composition assignments from these
technical triplicates.
Site-Specific Analysis of HDL Glycoproteins
Glycopeptides were assigned based on a combination of the
MS/MS data and the accurate precursor ion mass measure-
ment. The advantage of nonspecific digestion with Pronase is
the ability of the enzyme mixture to cleave the protein(s) into
short peptides with typically one glycosylation site. Previous
studies from our group on the analysis of nonspecific digested
glycopeptides with collision-induced dissociation (CID) experi-
Table 2. List of Glycopeptides from HDL Glycoproteins with Retention Time, Their m/z Values, Glycan Composition, the
Protein, the Sequence of the Peptide, and the Glycosylation Sitea
retention time (min) measured m/z charge state mass error (ppm) hexose HexNAc fucose NeuAc protein sequence site
24.893 967.7219 3 12.13 5 4 0 2 HEMO LPQPQN 453
25.338 945.7015 3 1.61 5 4 0 2 FETUA APLNDT 156
22.66 875.6656 3 11.12 5 4 0 2 TRFE SNVT 630
21.539 865.9789 3 7.70 5 4 0 2 FETUA NGSN 176
21.539 865.9789 3 7.70 5 4 0 2 APO-H GNNS 163
21.205 856.3226 3 8.25 5 4 0 2 KNG1 QTN 205
21.205 856.3226 3 13.68 5 4 0 2 A1AT GNAT 271
17.342 851.6635 3 14.67 5 4 0 2 FETUA NKS 432
23.225 851.3275 3 5.01 5 4 0 2 A1AT NLT 107
17.54 822.6527 3 9.53 5 4 0 2 ANGT KN 170
15.447 697.2652 3 17.33 5 4 1 0 A1AT NST 70
15.447 697.2652 3 19.91 5 4 1 0 ANGT NST 304
14.503 643.2539 3 4.78 4 4 1 0 HEMO NST 246
16.925 728.6016 3 19.26 5 4 0 1 ANGT HN 47
13.771 594.2537 2 0.93 1 1 0 1 FETUA VTSQP 256
13.957 594.2637 2 12.90 1 1 0 1 KNG1 KTEGP 542
14.090 572.243 2 6.96 1 1 0 1 FETUA QPSVG 346
21.75 721.3209 2 8.46 1 1 0 1 HEMO SLAIATPL 24
24.809 730.3203 2 6.19 1 1 0 2 FETUA VPTPV 270
19.01 739.8152 2 14.86 1 1 0 2 FETUA VTSQP 256
18.797 739.8152 2 1.976 1 1 0 2 APOCIII RPTSA 94
18.717 584.7726 2 18.75 1 1 0 1 FETUA VPTPV 270
26.005 830.3642 2 18.21 1 1 0 2 FETUA EAVPTPV 270
aAbbreviations: HEMO, hemopexin; FETUA, fetuin A; TRFE, serotransferrin; APO-H, apolipoprotein H; KNG1, kininogen-1; A1AT, alpha-1-
antitrypsin; ANGT, angiotensinogen; APOCIII, apolipoprotein CIII.
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ments revealed detailed and comprehensive glycan composi-
tional information for each glycopeptide (both N- and O-
linked).23,24 Glycosidic bond cleavages (B- and Y-type ions)
were the major products as well as some minor peptide
fragmentations.
Table 2 lists the Pronase-digested glycopeptides from HDL-
associated glycoproteins with their glycan composition,
glycosylation site, protein ID, and intensity. The most abundant
N-glycan (Hexose5HexNAc4Neu5Ac2) was found in multiple
glycoproteins from the glycopeptide assignment. Here, all the
identified proteins from the HDL were confirmed in triplicate
experiments using X! Tandem and were used in the
glycopeptide assignment search. A number of deconvoluted
glycopeptide MS/MS spectra are shown as examples in Figure
3. Figure 3A represents the MS/MS spectrum for a
triprotonated fetuin A glycopeptide containing this most
abundant disialylated N-glycan. Particularly unique to glyco-
peptides containing sialylated glycans are B-type ions
corresponding to neutral mass 291 Da (Neu5Ac) and neutral
mass 273 Da (Neu5Ac-H2O). Mass peaks also include those
observed as 203 Da, 365 Da, and 656 Da, which correspond to
the neutral masses of HexNAc, (Hex + HexNAc), and (Hex +
HexNAc + Neu5Ac). Because of the labile nature of sialic acid
residues and their positions at the termini, the initial loss of
sialic acid was commonly observed with the sialylated
glycopeptides. Following the sequential neutral losses of
monosaccharides of Neu5Ac, hexose, and HexNAc, the CID
data revealed the mass peak 832 Da corresponding to
glycopeptide (APLNDT + HexNAc). The presence of (peptide
+ HexNAc) is considered a valuable means for validating the
Figure 3. Deconvoluted MS/MS spectra of three sialylated glycopeptides. (A) MS/MS data for an N-linked glycopeptide from fetuin A in HDL
protein mixture; (B and C) MS/MS data for O-linked glycopeptides from apolipoprotein C3 and fetuin A, respectively.
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assignment of glycopeptide particularly when analyzing
complex protein mixtures.51
Pronase digestion simultanously enables site-specific analysis
of both N- and O-glycans. In addition to the abundant N-
glycans discussed previously, a number of O-glycopeptides were
present attached with sialylated O-glycans (Table 2). The
observed O-glycans associated with the HDL glycoproteins
were all sialylated, comfirming that HDL particles are highly
sialylated. Figure 3B,C revealed the deconvoluted MS/MS
spectra for two diprotonated O-glycopeptides from ApoC-III
and fetuin A, respectively. Most O-glycopeptides analyzed in
the HDL mixture contained a core 1 type with two Neu5Acs.
Figure 4 shows the site heterogeneity of four glycoproteins
from eight of the identified HDL associated glycoproteins as an
example. Fetuin A is a multifunctional circulating liver-derived
glycoprotein in serum and plasma.52 Several studies have
suggested that fetuin A may be critically important to
cardiovascular health.53−56 Both N- and O-glycans were
observed at multiple glycosylation sites with fetuin A, all of
which were sialylated (Figure 4A), which is consistent with the
previous glycosylation analysis on the individual protein fetuin
A.57 The most abundant glycan (Hexose5HexNAc4Neu5Ac2)
was disialylated and was found on most of the glycoproteins
examined. It was present at ASN156 and ASN176 of fetuin A.
Angiotensinogen is a heterogeneous glycoprotein mainly
produced by hepatocytes in plasma, which has a well-known
role in blood pressure regulation in animals and humans.58 It
has previously been shown that the glycosylation of
angiotensinogen may play a significant role in its functional
heterogeneity.59 Results of site heterogeneity of angiotensi-
nogen are summarized in Figure 4B. Among the four potential
N-glycosylation sites, three identified sites were occupied with
N-glycans in this study. While two sites were observed
associated with sialylated N-glycans, site ASN304 was attached
with fucosylated N-glycans. Angiotensinogen was also found
attached with the most abundant sialylated glycan (Hex-
ose5HexNAc4Neu5Ac2) at ASN
170.
Figure 4C details the glycan associated with alpha-1B-
glycoprotein (A1BG). A1BG is believed to be a member of the
immunoglobulin family.60 The monosialylated glycan (Hex-
ose5HexNAc4Neu5Ac1) attached at ASN
363 on A1BG.
The glycosylation of apolipoprotein C3 (ApoC-III) was
analyzed by a couple of groups, showing the distribution of O-
glycans.61,62 The disialylated O-glycan at site Thr94 from ApoC-
III is shown in Figure 4D. ApoC-III inhibits lipoprotein lipase
and hepatic lipase, thought to inhibit hepatic uptake of
triglyceride-rich particles.63 ApoC-III was also recently found
to be increased in HDL isolated from patients with both stable
coronary artery disease and acute coronary syndrome as well as
in hemodialysis patients.64,65
In general, for the first time the site-specific glycosylation of
these proteins in HDL particles has been described. Compared
with previous disscussed glycan analysis, some glycans were not
observed in the glycopeptide analysis due to their low
abundances as well as the potential short peptide length from
Pronase digestion. However, the functions they impart on HDL
through their glycosylation, and whether alterations in their
glycosylation as part of HDL particles is either causative or
diagnostic in disease, are unknown.
HDL Gangliosides Characterized by MS/MS
Gangliosides are another contributor of sialic acid in HDL. We
applied a high resolution quadrupole time of flight mass
spectrometry (Q-TOF MS) method with reverse-phase
nanoHPLC separation for the analysis of human HDL
gangliosides. The high mass accuracy of these instruments,
along with the MS/MS capability, made it possible to perform
focused detection of ganglioside species in the polar lipid
extract.66 Postprocessing precursor ion scans indicate the
existence of gangliosides, which elute at certain retention
times. Moreover, based on accurate mass, glycan information
and ceramide composition were simultaneously obtained.
Figure 5 is representative of the ECCs of HDL gangliosides.
The chromatogram reveals an elution pattern starting with
gangliosides with shorter ceramide chains followed by those
with longer ceramides. Examination of the profiles shows that
GM3 (monosialoganglioside, NeuAc2−3Gal1−4Glc−Cer) and
GD3 (disialoganglioside, NeuAc2−8NeuAc2−3Gal1−4Glc−
Cer) were abundant ganglioside ions in HDL from healthy
Figure 4. Glycan site-heterogeneity of HDL associated glycoprotein (A) fetuin A (alpha-2-HS-glycoprotein), (B) angiotensinogen, (C) alpha-1B-
glycoprotein, and (D) apolipoprotein CIII.
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human plasma, in agreement with earlier studies.67 Eight GM3
and four GD3 gangliosides were detected. A 60% GM3 and
40% GD3 distribution was observed, and ion intensities were
measured in the MS mode based on the deprotonated
molecular ion (Table 3). Interestingly, the composition of
human aorta from patients who had died of myocardial
infarction were found to have higher GD3 content in the aortic
media versus the intima,68 and total ganglioside content was
found to be lower in cells isolated from atherosclerotic
compared with normal human aorta.69 Gangliosides have
even been found to stimulate lipoxygenase-mediated eicosanoid
production in peripheral blood lymphocytes, and GD3 was
more stimulatory compared with GM1 or GM3.70 These
previous reports suggest that ganglioside content and
composition may have important biological implications in
heart disease and its related mechanisms involving lipoproteins.
The analysis also revealed the composition of the major
ceramide portion of GM3 and GD3 gangliosides. Both GM3
and GD3 were composed of heterogeneous ceramide lipid tails,
including d18:1/16:0 and d18:1/23:0. Types of sphingoid bases
and fatty acids in the backbones were determined with the use
of 80 V MS/MS. Fragments at m/z 264.269 and at m/z
236.238 indicated the existence of sphingoid bases d18:1 and
d16:1, respectively. As an example, GM3 (d18:1/16:0) yields a
diagnostic sialic acid fragment at m/z 290.09 in 40 V negative
mode MS/MS, while 80 V positive mode MS/MS spectrum
provides the ceramide information at m/z 520.49 and 264.27
(Supplemental Figure S2, Supporting Information). The
importance of the ceramide lipid tail compositional differences
is currently poorly understood. For example, transmembrane
anchored angiotensin converting enzyme, an enzyme important
for blood pressure regulation, was found to associate only with
C18 but not C16 sphingomyelin-containing rafts.71 A recent
report showed that nascent HDL resemble lipid rafts,
suggesting the possibility that HDL particles have micro-
heterogeneity with lipid raftlike portions of the phospholipid
outer layer that recruit specific gangliosides and proteins to
perform specific functions, just as occurs in plasma membrane
lipid rafts.72 The simultaneous identification of the glycan and
ceramide will provide a clearer picture of the role of
gangliosides in lipoprotein biology.
■ CONCLUSION
We have established analytical methods for profiling the
glycome of HDL particles. The approach detailed here provides
a simultaneous and detailed analysis of glycoproteins (both N-
and O-glycan composition, as well as site-specific glycopeptide
composition) and gangliosides (both the glycan and ceramide
portion) that was previously not achievable. The methods
developed in this study can be used for the analysis of other
nanobioparticles including LDL, VLDL, and chylomicrons, as
well as the various size subclasses of these major lipoprotein
classes. This approach will have implications for elucidating a
number of biological functions of HDL. With this method in
place, it is now possible to conduct an array of experiments and
analyses of clinical samples to understand the important
biological functions and diagnostic potential of HDL that are
mediated by glycans.
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retention time (min) measured m/z charge state mass error (ppm) structural assignment ion intensity (counts)
12.9 1151.711 −1 −4.3 GM3(d18:1/16:0) 1120103
16.2 1179.732 −1 4.2 GM3(d16:1/20:0) or GM3(d18:1/18:0) 498901
19.7 1207.760 −1 7.5 GM3(d16:1/22:0) 459570
21.4 1221.779 −1 4.1 GM3(d16:1/23:0) 288025
22.9 1235.793 −1 5.7 GM3(d16:1/24:0) or GM3(d18:1/22:0) 772085
24.3 1249.812 −1 2.4 GM3(d16:1/25:0) or GM3(d18:1/23:0) 543404
25.8 1263.833 −1 −1.6 GM3(d18:1/24:0) 494824
26.7 1277.849 −1 −1.6 GM3(d18:1/25:0) 42591
20.2 755.935 −2 1.3 GD3(d16:1/23:0) 455116
21.4 762.945 −2 −1.3 GD3(d16:1/24:0) or GD3(d18:1/22:0) 1006020
23.1 769.972 −2 1.3 GD3(d16:1/25:0) or GD3(d18:1/23:0) 815475
24.7 776.960 −2 0.0 GD3(d18:1/24:0) 523004
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